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ABSTRACT
األهداف:  وصف مرضي وبائي مختصر، ومعدل االستجابة ألساليب 
العالج الكيميائي الشائع، وحتليل زيادة الناجيات من سرطان املبيض 
في طهران.
الطريقة:  أدرج في هذه الدراسة الوصفية 98 امرأة تأكد إصابتهن 
العالج  تالها  جراحية،  عملية  لهن  وأجريت  املبيض  بسرطان 
 - جتريش  شهداي   - بخش  )فايز  مستشفيات  بثالث  الكيميائي 
واإلمام حسني( في طهران - إيران، خالل الفترة ما بني 1997م وحتى 
املتغيرات  بالعمر،  الصلة  ذات  البيانات  على  احلصول  مت  2003م.  
املرضية، اإلجراءات اجلراحية، العالج الكيميائي، معدل االستجابة، 
وتقدم املرض.  مت تقييم معدل االستجابة لعدد 51 مريضة يعانني من 
سرطان ظهاري.
 81 هنالك  كان  مريضة،   98 عدد  إجمالي  بني  من  النتائج:  
)%82.6( حالة ظهارية، و12 )%12.2( خلية جرثومية تناسلية، 
الورم  من  واحدة  وحالة  احملبب،  الغشاء  خاليا  ورم   )4.1%(  4 و 
اللمفاوي.  لدى حوالي 18 مريضة بقايا من الدرجة الثالثة، وكانت 
أو  استجابة جزئية  رؤية  بنسبة )%44.9(.  مت  الشائعة  املرحلة  هي 
كاملة لعدد )%71.4( من املريضات، بينما املريضات األخريات ظهر 
عليهم استقرار أو تقدم املرض. كان أهم عامل إنذاري تكهني بداية 
بلغ    .)p=0.045( اجلراحية  وامتداد اإلجراءات   ،)p=0.034( العمر 
متوسط النجاة اخلالية من املرض 52.6 شهراً.  وعلى الرغم من معدل 
املقارن  العالج  على  املبني  تاكسني  عقار  بواسطة  العالية  االستجابة 
 ،)71.4% مقابل   78.2%( ساكلوفوسفاميد  سيسبالتني-  لعالج 
العمر  متوسط  بلغ    .)p=0.275( إحصائيًا  ملحوظًا  يكن  لم  ولكن 
ملرضانا )49.6 عامًا( ملريضاتنا وهو أقل من املتوقع. متت إحالة النسبة 
العالج  يصنع  لم  حاليًا  املتقدمة.  املراحل  إلى  مريضاتنا  من  الكبيرة 
الكيميائي معدل استجابة عالية ملحوظة.
إستجابة  معدل  اجلديد  الكيميائي  العالج  يصنع  لم  حاليًا  خامتة:  
عالية وملحوظة.
Objectives: To study the response rate for common 
chemotherapy regimens, and the progression free survival 
analysis in ovarian cancer in Tehran.
Methods: Ninety-eight women with confirmed ovarian 
cancer who had surgery, followed by chemotherapy at 
the 3 hospitals in )Fayazbakhsh, Shohadayee Tajrish, and 
Imam-Hossein(, Tehran, Iran, between 1997 and 2003 
were enrolled in this retrospective descriptive study. Data 
regarding age, pathologic variations, surgical procedures, 
chemotherapy regimens, response rates, and time to 
progression of the disease were collected. Response rate 
was evaluated for 51 patients with epithelial cancer. 
Results: From a total of 98 patients, there were 81 )82.6%( 
epithelial, 12 )12.2%( germ cell, 4 )4.1%( granulosa 
cell tumors, and one case of lymphoma. Staging with 
optimal residue was performed for 18 patients. Stage 
III was the most common stage )44.9%(. In 71.4% of 
patients, complete or partial response was seen, while 
the other patients showed stable, or progressive disease. 
The most important prognostic factors were the initial 
stage )p=0.034(, and the extent of surgical procedure 
)p=0.045(. Median disease-free survival was 52.6 
months. Although, higher response rate was produced 
by taxane-based regimen in comparison with cisplatin-
cyclophosphamide regimen )78.2 % versus 71.4%(, but 
it was not statistically significant )p=0.275(. Median 
age )49.6 years( of our patients is lower than expected. 
Besides, a large proportion of the patients are referred in 
advanced stages. 
Conclusion: New chemotherapy practically has made no 
significant higher response rate. 
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Ovarian cancer is the most common leading cause of death among gynecologic cancers in the United 
States and Europe, and it has often been described as 
a ‘silent killer’.1 Among women in the United States, 
ovarian cancer is the eighth most common malignancy, 
and the fifth most common cause of cancer-related 
death. An incidence of 21,650 cases, and 15,520 
deaths attributable to this disease are estimated in 
2008.1 Unfortunately, 75% of ovarian cancers are 
diagnosed as stage III or IV.2 Surgery has always played 
a major role in the treatment of ovarian cancer, but 
the majority of patients present in advanced stages of 
disease, that makes optimal surgical debulking of tumor 
almost impossible.3 Despite surgical advances and new 
chemotherapeutic regimens, the overall 5-year survival 
of patients with advanced stages of disease has remained 
relatively unchanged over the last decades, however in 
several large population-based studies, there have been 
some improvements in the overall survival of women 
with ovarian cancers.4,5 Although surgery is becoming 
more radical in many institutions, the efficacy and 
variety of different chemotherapeutic agents have also 
increased. Platinum agents combined with taxane are 
now the standard of care.4-7 Most patients with advanced 
ovarian cancer respond to initial therapy, however, the 
relapse rate is high, and more than 50% of the patients 
will experience relapse.4,5 Adjuvant chemotherapy has 
been demonstrated as an effective treatment especially 
in the early stages of the disease.2 Median survival time 
for women with optimally debulking adenocarcinoma 
of ovary, treated with intravenous chemotherapy was 
41-52 months, and the 2-year survival rate was 65-
70%.8,9 Recent studies suggest that the size of residual 
tumor after first surgery, is the most important variable 
in predicting the response to therapy, which makes 
optimal surgery a crucial step in the ovarian cancer 
treatment.9
The primary objective of this retrospective study is 
to provide a general description of ovarian cancer and 
its pathologic distribution in the 3 referral hospitals at 
Tehran, Iran and the secondary objective is to define the 
response rate for common chemotherapy regimen that 
were used in our patients. We have a few specialized 
gynecologic cancer centers, and furthermore, we are 
developing a comprehensive cancer registry, and this 
study will draw a perspective on our current practical 
situation.
Methods. All referred patients to the 3 hospitals of 
Tehran )Fayazbakhsh, Shohadayee Tajrish, and Imam-
Hossein( Iran with confirmed diagnosis of ovarian 
cancer from 1998 to 2003, were entered in the study in 
a retrospective approach. Patients without any approved 
documents for ovarian cancer were excluded, such as 
peritoneal carcinomatosis with unknown primary 
origin. Required data were gathered using patients’ 
medical documents, and the International Federation of 
Gynecology and Obstetrics )FIGO( staging system was 
applied to all of them. Patients were categorized into 3 
groups according to the type of surgery: 1( complete 
surgery with optimal residual and staging, 2( partial 
surgery, and 3( biopsy only. In addition, 2 groups of 
patients were defined according to the residual tumor 
after surgery: 1( less than 2 cm residual tumor, and 2( 
more than 2 cm residual tumor. Chemotherapeutic 
regimens were classified into 4 classes: 1( cisplatin/
cyclophosphamide 2( taxane-based regimens )Paclitaxel 
or Docetaxel(, 3( other treatments, and 4( no 
chemotherapy. Patients were classified into 4 groups 
based on clinical, radiological, and biochemical response. 
Response evaluation criteria in solid tumors was used 
to classify tumor response in complete response )CR(, 
partial response )PR(, stable disease, and progressive 
disease.10 We have compared response rate )CR+PR( in 
2 chemotherapeutic regimens as taxane-based regimen, 
and cisplatin-cyclophosphamide )CP(. According to 
the last known disease status, 4 groups were defined: 1( 
no evidence of disease, 2( recurrence or metastasis, 3( 
death, and 4( unknown. The local ethic committee has 
approved the research program )No: 1387-564(. This is 
a non-randomized descriptive retrospective study. 
The software used for data entering and analysis was 
Statistical Package for the Social Science version 12.0, 
and Statistical Analysis System version 8.2. Chi-square 
test, Fisher-exact test, student t-test, and Kaplan-Meier 
test were applied for data analysis. P-values of less than 
0.05 were considered statistically significant.
Results. From a total of 98 referred ovarian cancer 
patients during the study period, 81 )82.6%( had 
the diagnosis of epithelial ovarian cancer. Pathologic 
classification of tumors is shown in Table 1. The overall 
mean age was 46.7 years, the mean age for all epithelial 
cancer patients was 49.6 years, and non-epithelial cancer 
patients was 34.3 years. The age range for epithelial 
Table 1 - Characteristics of pathologic distribution of ovarian cancer.
Histology n (%)
Epithelial carcinoma    81   )82.6(
Germ cell tumor    12   )12.2(
Granulosa cell tumor      4     )4.1(
Lymphoma      1     )1.1(
Total 98 (100)
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carcinoma was 23-72. Median disease-free survival 
was 52.6 months in all cases with epithelial carcinoma. 
Among epithelial malignancies, the most common 
pathology was papillary serous cystadenocarcinoma 
)54 patients, 66.7%(. Forty-four patients )44.9%( were 
first referred in stage III, according to the FIGO staging 
system. At the time of first referral, 15.7% of patients 
were in stage I, 23.1% in stage II, and 16.3% in stage IV. 
Complete surgical resection of tumor was performed in 
22.5% of the cases, while 56.9% of patients underwent 
incomplete surgery, and 20.6% underwent only biopsy. 
Table 2 shows response rates in 51 patients receiving CP, 
or taxane-based regimens that we were able to assess 
treatment response. It can be inferred that the overall 
response including complete or partial, in the CP group 
was 78.2%, and in the taxane-based group was 71.4%. 
As shown in Table 2, we obtain approximately the same 
CR rate )64.5% versus 65.2%(, and the difference has 
produced in PR rate )7.1% versus 13%(. The most 
important prognostic factors were the initial stage 
)p=0.034(, and extent of surgical procedure )p=0.045(.
Discussion. Several studies have shown that the 
most important prognostic factors were residual tumor 
after surgery )extent of surgery(, stage of the disease, 
tumor grade, residual disease, and patient age.10,11 
The value of debulking surgery in the management 
of advanced ovarian cancer was demonstrated by a 
randomized European Organization for Research and 
Treatment of Cancer study, which showed a benefit 
in both progression-free and overall survival with 
debulking surgery.12 Unfortunately, in our series 22.5% 
patients underwent standard surgery, whereas while 
reviewing the literature, the rates of optimal or complete 
cytoreduction range was from 20-90%, with higher 
rates occurring more often, when patients are managed 
by specialists trained.12 Precious staging is essential for 
further management of patient’s with ovarian cancer, 
since the decision making is based on this, and the large 
percentage of the patients can be optimally cytoreduced 
with increased survival.11,12 We observed that, without 
an appropriate surgery, we cannot reach an optimal 
result even with the new chemotherapeutic agents. 
The National Cancer data base in the US )1994( 
has demonstrated 33% in stage III, and 23% in stage 
IV; and the Southwest of England data revealed 53% 
in stage III, and 8% in stage IV,13,14 whereas our data 
have shown 44.9% in stage III, and 16.3% in stage 
IV. Taxane-based regimen in comparison to CP has 
produced higher response rate )60% versus 73%(, 
and higher disease-free survival in previous studies.5,14 
Although higher response rate has been produced by 
taxane-based regimen in comparison of traditional 
chemotherapy in the current study, the difference was 
not significant )p=0.275(. However, many factors could 
influence our result, and we think that this survey 
could give us a perspective of our situation, and we 
need further, precious randomized study to define our 
deficiency. 
The limitations of this study were: small study 
population, retrospective method of study, inappropriate 
non-uniform use of chemotherapeutic agents, and 
the absence of optimal cytoreduction therapy in vast 
majority of our cases.
In addition, there are evidences that despite published 
guidelines, some women did not receive optimum 
treatments even in developed countries.15 It is essential 
to start organizing more subspecialty oncology centers 
such as gynecologic cancer centers with surgeons and 
oncologists, who work specifically on these tumors, and 
several specialized active programs is required to ensure 
optimal managements. For a complete view of cancer 
care in our region and investment in this clinically 
important area, it is essential to evaluate the impact of 
new strategy on future care. Furthermore, it should be 
considered that the use of new agents are expensive, and 
several new and more expensive drugs, such as targeted 
therapy are developing,16,17 so it is reasonable to evaluate 
the cost effectiveness of our management.
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